Entering text into the input field will update the search result below

International Stem Cell Corp. (ISCO) Not Limited To A Particular Stem Cell Application

Jul. 15, 2013 5:55 PM ETISCO
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Every living thing owes its existence to cells, with the average adult human body made up of nearly 100 trillion of them. So it's not surprising that cellular processes are at the heart of human disease. And, since stem cells are the ultimate source cells from which specialized cells are generated, stem cell technology is seen as a powerful tool for overcoming a wide range of diseases. So many new discoveries and applications are now being experienced that the overall stem cell market is seen by some as being virtually boundless.

The advantage of International Stem Cell Corporation is that the company is not limited to a particular application or disease. Instead they've invented a new stem cell platform, a new technology called parthenogenesis that utilizes unfertilized human eggs to create a type of stem cell that has two important advantages over other stem cells.

First, it avoids the controversy associated with the use of stem cells from human embryos. Second, parthenogenetic stem cells (hpSC), because of the unique way they are generated, can be immune matched to millions of different people, overcoming the serious problem of immune rejection. As a result, a relatively small number hpSC lines could provide sufficient immune-matched cells to cover a large percentage of the world's population.

The company is now engaged in establishing the efficacy of parthenogenetic stem cells in the treatment of various diseases:

• The treatment of Parkinson's disease using dopaminergic neurons - ISCO scientists are focused on deriving neuronal cells, and have developed a method of creating pure populations of cells suitable for implantation. ISCO has also recently demonstrated that Parkinson's symptoms can be successfully treated with the company's unique parthenogenetic stem cell derived neuronal cells.

• The treatment of liver disease with stem cell derived hepatocytes - ISCO's scientific team are focused on developing better methods to create pure populations of hepatocyte that could be used in transplantation using HLA homozygous parthenogenetic stem cell lines to avoid the cells being immune rejected.

• The treatment of blindness with corneal tissue - Scientists at ISCO have developed and filed patents on a process that creates human corneal tissue from parthenogenetic stem cells, a tissue that closely resembles a human cornea in structure and cell types.

For more information, visit internationalstemcell.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.